Last updated: 12/18/2025 10:10:20
Safety and Immunogenicity Study of GSK’s Clostridium difficile Vaccine 2904545A When Administered in Healthy Adults Aged 18-45 Years and 50-70 Years
EudraCT ID
EU CT Number
Not applicable
Trial status
Study complete
Study complete
Trial overview
Official title: A Phase I, Single-center, Randomized, Observer-blind, Placebo-controlled Study to Evaluate Safety, Reactogenicity and Immunogenicity of GSK’s Clostridium difficile Investigational Vaccine Based on the F2 Antigen With or Without AS01B Adjuvant, When Administered Intramuscularly According to a 0, 1-month Schedule to Healthy Adults Aged Between 18-45 Years and Between 50-70 Years, Followed by an Additional Dose Administered in a Partial blind Manner Within an Interval of Approximately 15 Months After Dose 2, in a Subcohort of Subjects aged 50-70 Years
Trial description: The purpose of this study is to generate safety, reactogenicity (assessment of any expected or unexpected side effect of the vaccine) and immunogenicity (ability to induce an immune response) data for the development of a candidate Clostridium difficile (C. difficile) vaccine that would protect against primary cases of Clostridium difficile infection (CDI) and CDI recurrence.Clostridium difficile infection is a major cause of gastrointestinal illness with approximately 500,000 infections and the leading cause of gastroenteritis associated death with 29,000 deaths annually in the United States of America (USA). The emergence of extremely infectious varieties/types of C. difficile has contributed to increase the number and severity of CDI cases. In recent years, some countries (United Kingdom) have implemented hospital hygiene and other measures which resulted in significant reductions in the number of cases. The burden is, however, expected to remain significant until vaccination is available.
Primary purpose:
Prevention
Trial design:
Sequential Assignment
Masking:
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Allocation:
Randomized
Primary outcomes:
Number of subjects with any and Grade 3 solicited local symptoms, after each vaccine dose
Timeframe: During the 7-day follow-up period (from the day of vaccination up to 6 subsequent days) after each vaccination
Number of subjects with any, Grade 3, related and Grade 3 related solicited general symptoms, after each vaccine dose
Timeframe: During the 7-day follow-up period (from the day of vaccination up to 6 subsequent days) after each vaccination
Number of subjects with any, Grade 3, related, Grade 3 related and medically attended unsolicited adverse events (AEs)
Timeframe: During the 30-day follow-up period (from the day of vaccination up to 29 subsequent days) after any vaccination
Number of subjects with serious adverse events (SAEs)
Timeframe: From Day 1 up to and including Day 390 (Epoch 001)
Number of subjects with potential immune-mediated diseases (pIMDs)
Timeframe: During the whole study period (from Day 1 up to Day 390 [for subjects receiving 2 vaccine doses] and from Day 1 up to Day 670 [for subjects receiving 3 vaccine doses])
Number of subjects with hematological, biochemical, and urinary laboratory abnormalities at Screening
Timeframe: At Screening (from Day -15 up to Day -1 [for subjects receiving 2 vaccine doses] and at Day 476 [for subjects receiving 3 vaccine doses])
Number of subjects with hematological and biochemical laboratory abnormalities at Day 8
Timeframe: At Day 8
Number of subjects with hematological and biochemical laboratory abnormalities at Day 31
Timeframe: At Day 31
Number of subjects with hematological and biochemical laboratory abnormalities at Day 38
Timeframe: At Day 38
Number of subjects with hematological and biochemical laboratory abnormalities at Day 180
Timeframe: At Day 180
Number of subjects with hematological and biochemical laboratory abnormalities at Day 390
Timeframe: At Day 390
Number of subjects with hematological and biochemical laboratory abnormalities at Day 476
Timeframe: At Day 476
Number of subjects with hematological and biochemical laboratory abnormalities at Day 491
Timeframe: At Day 491
Number of subjects with hematological and biochemical laboratory abnormalities at Day 670
Timeframe: At Day 670
Secondary outcomes:
Serum neutralizing anti-Toxin A and anti-Toxin B antibody titers, as measured by Toxin Neutralization Assay (TNA)
Timeframe: At Day 1, Day 31, Day 61, Day 180, Day 390, Day 491, Day 521 and Day 670
Interventions:
Enrollment:
140
Primary completion date:
2022-10-05
Observational study model:
Not applicable
Time perspective:
Not applicable
Clinical publications:
Leroux-Roels I, Alhatemi A, Caubet M, De Boever F, De Wergifosse B, EL IDRISSI M, et al. . CLI_C-Diff004: 208109_Safety, reactogenicity and immunogenicity of an adjuvanted C. difficile vaccine candidate in healthy adults: a randomised placebo-controlled phase I study _BxB. J Infect Dis. https://academic.oup.com/jid/advance-article/doi/10.1093/infdis/jiae466/7839841
DOI: 10.1093/infdis/jiae466
PMID: 39447053
Medical condition
Clostridium Infections
Product
GSK2904545A
Collaborators
Not applicable
Study date(s)
August 2019 to May 2022
Type
Interventional
Phase
1
Participation criteria
Sex
Female & Male
Age
18 - 70 Years
Accepts healthy volunteers
Yes
- 1. Subjects who, in the opinion of the Investigator, can and will comply with the requirements of the protocol.
- 2. Written or witnessed/thumb print informed consent obtained from the subject prior to performance of any study specific procedure.
- 1. Health condition that, in the opinion of the Investigator, may interfere with optimal participation in the study or place the volunteer at increased risk of AEs. Study clinicians, in consultation with the Principal Investigator will use clinical judgment on a case by case basis to assess safety risks under this criterion. The Principal Investigator will consult with the Medical Monitor as appropriate.
- 2. Use of any investigational or nonregistered product other than the study vaccine(s) during the period starting 30 days before the first dose of study vaccine(s) (Day 29 to Day 1), or planned use during the study period.
Inclusion and exclusion criteria
Inclusion criteria:
- 1. Subjects who, in the opinion of the Investigator, can and will comply with the requirements of the protocol. 2. Written or witnessed/thumb print informed consent obtained from the subject prior to performance of any study specific procedure. 3. For Step 1 only: A male or female between, and including, 18-45 years of age at the time of the first vaccination. 4. For Steps 2, 3, and 4: A male or female between, and including, 50-70 years of age at the time of the first vaccination. 5. Healthy subjects as established by medical history and clinical examination before entering into the study. 6. Subjects free of any uncontrolled chronic illnesses as established by medical history and clinical examination before entering into the study. 7. Female subjects of non-childbearing potential may be enrolled in the study.
- Non-childbearing potential is defined as premenarche, current bilateral tubal ligation or occlusion, hysterectomy, bilateral ovariectomy, or post-menopause. Female subjects of childbearing potential may be enrolled in the study, if the subject:
- Has practiced adequate contraception for 30 days prior to vaccination, and
- Has a negative urine pregnancy test on the day of vaccination, and
- Has agreed to continue adequate contraception during the entire treatment period and for 2 months after completion of the vaccination series.
Exclusion criteria:
- 1. Health condition that, in the opinion of the Investigator, may interfere with optimal participation in the study or place the volunteer at increased risk of AEs. Study clinicians, in consultation with the Principal Investigator will use clinical judgment on a case by case basis to assess safety risks under this criterion. The Principal Investigator will consult with the Medical Monitor as appropriate. 2. Use of any investigational or nonregistered product other than the study vaccine(s) during the period starting 30 days before the first dose of study vaccine(s) (Day 29 to Day 1), or planned use during the study period. 3. Any medical condition that in the judgment of the Investigator would make IM injection unsafe and subjects under treatment with anticoagulant therapy. 4. Chronic administration of immunosuppressants or other immune modifying drugs during the period starting 3 months prior to the first vaccination. For corticosteroids, this will mean prednisone ≥ 5 milligrams per day (mg/day) (for adult subjects), or equivalent. Inhaled and topical steroids are allowed. 5. Administration of long acting immune modifying drugs at any time during the study period. 6. Administration of immunosuppressive therapy, including chemotherapeutic agents used to treat cancer or other conditions, and treatments associated with organ or bone marrow transplantation or autoimmune disease. 7. Administration of immunoglobulins and/or any blood products during the period starting 3 months before the first vaccination of study treatment or planned administration during the study period. 8. Planned administration/administration of a vaccine not foreseen by the study protocol in the period starting 6 weeks before the first vaccination and ending 6 weeks after the last vaccination, with the exception of inactivated influenza vaccine which can be administered up to 14 days before or from 30 days after the last study vaccination. In case an emergency mass vaccination for an unforeseen public health threat (eg, a pandemic) is recommended and/or organized by public health authorities outside the routine immunization program, the time period described above can be reduced if, necessary for that vaccine, provided it is used according to the local governmental recommendations and that the Sponsor is notified accordingly. 9. Planned administration of GSK’s Herpes Zoster vaccine marketed as Shingrix or an adjuvanted recombinant varicella zoster virus envelope gE subunit vaccine (HZ/su) within 180 days before the first dose and within 180 days after the last dose of the study vaccine. 10. Planned elective surgery during the study period. 11. Concurrently participating in another clinical study, at any time during the study period, in which the subject has been or will be exposed to an investigational or a non-investigational vaccine/product. 12. Body mass index < 19 kg/m^2 or ≥ 35 kg/m^2. 13. Clinically relevant physical examination abnormalities. 14. For subjects aged 18 – 45 years, Grade 2 or higher abnormal hematological, biochemical, and urinary parameters. 15. For subjects aged 50 – 70 years, Grade 3 or higher abnormal hematological, biochemical, and urinary parameters. 16. Documentation of current or prior episode of CDI. 17. Any confirmed or suspected immunosuppressive or immunodeficient condition, based on medical history and physical examination (no laboratory testing required). 18. Recurrent history or uncontrolled neurological disorders or seizures. 19. Family history of congenital or hereditary immunodeficiency. 20. History of any reaction or hypersensitivity likely to be exacerbated by any component of the vaccines. 21. Acute disease and/or fever at the time of enrollment.
- Fever is defined as temperature ≥ 38.0°C/100.4°F. The preferred location for measuring temperature in this study will be the oral cavity.
- Subjects with a minor illness, without fever, may be enrolled at the discretion of the Investigator. 22. Acute or chronic, clinically significant pulmonary, cardiovascular, hepatic, or renal functional abnormality, as determined by physical examination or laboratory screening tests. 23. Pregnant or lactating female. 24. History of intestinal bleeding or history of diverticular intestinal bleeding. 25. Surgery for gastrointestinal malignancy in the period starting 3 months prior to the first vaccination. 26. History of chronic alcohol consumption and/or drug abuse as deemed by the Investigator to render the potential subject unable/unlikely to provide accurate safety reports. 27. Female planning to become pregnant or planning to discontinue contraceptive precautions. 28. Documented human immunodeficiency virus positive subject, known positivity for the surface antigen of the hepatitis B virus or known positive serologic test for the hepatitis C virus. 29. Involvement in the planning and/or conduct of the study.
Trial location(s)
Study documents
Study report synopsis
Available language(s): English
Protocol
Available language(s): English
Statistical analysis plan
Available language(s): English
If you wish to request for full study report, please contact - [email protected]
Results overview
Results posted on ClinicalTrials.gov
Recruitment status
Study complete
Actual primary completion date
2022-10-05
Actual study completion date
2022-10-05
Plain language summaries
Plain language summaries of clinical trial results for Phase 2-4 clinical trials that were initiated on or after January 2022 will be posted by GSK within one year following study completion.
Additional information about the trial
Additional information
Not applicable
Participate in clinical trial
Access to clinical trial data by researchers
Visit website